Abstract
The penetration into the eye and the systemic absorption of 2% cyclosporin eye drops were determined by polarisation immunofluorescent assay of cyclosporin in the aqueous humour and plasma of 30 patients at the time of cataract surgery. The results were then compared with the corresponding results after oral administration at a dosage of 5 mg/kg/day to three further patients. The maximum intraocular concentration (24 (SD 9) mg/l) was achieved four hours after topical administration. This level was slightly less than that found in aqueous humour (28 (SD 10) mg/l) 12 hours after systemic administration of the drug at a dosage of 5 mg/kg/day. Both these levels are below the minimum therapeutic level (50-100 mg/l). Topical application of cyclosporin A did not produce detectable levels in plasma at any time. These results indicate that the efficacy of cyclosporin A in the control of intraocular inflammation is attributable to its systemic immunoregulatory effect rather than to the local ocular effect.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bell T. A., Easty D. L., McCullagh K. G. A placebo-controlled blind trial of cyclosporin-A in prevention of corneal graft rejection in rabbits. Br J Ophthalmol. 1982 May;66(5):303–308. doi: 10.1136/bjo.66.5.303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bell T. A., Hunnisett A. G. Cyclosporin A: tissue levels following topical and systemic administration to rabbits. Br J Ophthalmol. 1986 Nov;70(11):852–855. doi: 10.1136/bjo.70.11.852. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hunter P. A., Garner A., Wilhelmus K. R., Rice N. S., Jones B. R. Corneal graft rejection: a new rabbit model and cyclosporin-A. Br J Ophthalmol. 1982 May;66(5):292–302. doi: 10.1136/bjo.66.5.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kana J. S., Hoffmann F., Buchen R., Krolik A., Wiederholt M. Rabbit corneal allograft survival following topical administration of cyclosporin A. Invest Ophthalmol Vis Sci. 1982 May;22(5):686–690. [PubMed] [Google Scholar]
- Leapman S. B., Filo R. S., Smith E. J., Smith P. G. Differential effects of cyclosporin-A on lymphocyte subpopulations. Transplant Proc. 1981 Mar;13(1 Pt 1):405–409. [PubMed] [Google Scholar]
- Mosteller M. W., Gebhardt B. M., Hamilton A. M., Kaufman H. E. Penetration of topical cyclosporine into the rabbit cornea, aqueous humor, and serum. Arch Ophthalmol. 1985 Jan;103(1):101–102. doi: 10.1001/archopht.1985.01050010107030. [DOI] [PubMed] [Google Scholar]
- Nussenblatt R. B., Dinning W. J., Fujikawa L. S., Chan C. C., Palestine A. G. Local cyclosporine therapy for experimental autoimmune uveitis in rats. Arch Ophthalmol. 1985 Oct;103(10):1559–1562. doi: 10.1001/archopht.1985.01050100135035. [DOI] [PubMed] [Google Scholar]
- Nussenblatt R. B., Palestine A. G., Chan C. C. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983 Sep;96(3):275–282. doi: 10.1016/s0002-9394(14)77814-6. [DOI] [PubMed] [Google Scholar]
- Nussenblatt R. B., Palestine A. G. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986 Nov-Dec;31(3):159–169. doi: 10.1016/0039-6257(86)90035-4. [DOI] [PubMed] [Google Scholar]
- Nussenblatt R. B., Palestine A. G., Rook A. H., Scher I., Wacker W. B., Gery I. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. 1983 Jul 30;2(8344):235–238. doi: 10.1016/s0140-6736(83)90230-1. [DOI] [PubMed] [Google Scholar]
- Salisbury J. D., Gebhardt B. M. Suppression of corneal allograft rejection by cyclosporin A. Arch Ophthalmol. 1981 Sep;99(9):1640–1643. doi: 10.1001/archopht.1981.03930020514024. [DOI] [PubMed] [Google Scholar]